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Abstract 
Cancer is becoming an ever-growing focus of the medical and research fields with 
regards to treatment and elimination. Pancreatic cancer is the fourth leading cause of death in the 
United States due to the difficulty in detection and treatment. The current survival rate over five 
years is 4%. Many possible treatments for pancreatic cancer currently exist; however, is difficult 
to deliver large amount of toxic cancer drugs to targeted tumor sites without significant and often 
deadly side effects for patients. Nanometer-scale drug delivery vehicles have proven to be one 
advantageous method to reduce drug toxicity. The goal of this project is to explore the use of 
self-assembling nanotubes based on peptide-camptothecin derivatives to allow for increased 
targeting of cancer cells during the course of treatment. Three compounds were formed from 
camptothecin, succinic acid and lysine derivatives- lysine methyl ester, lysine, lysine amide. 
They were tested in water and phosphate buffer solution (PBS), mimicking biological conditions, 
for their solubility and ability to self-assemble into specific and stable aggregates.  The soluble 
compounds were tested and imaged for confirmation of nanostructures and identification of self-
assembly process via transmission electron microscopy and circular dichroism scans. The methyl 
ester form (1.0) created nanotubes in water while the free acid form (2.0) and amide form (3.0) 
created nanotubes in PBS. The potential for a dynamic system was tested but modifications to 
the design must be made to take advantage of this characteristic and perfect the drug delivery 
system. 
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Abbreviations: 
Alloc: allyloxycarbonyl 
Boc: tert-butyloxycarbony 
Chloro-trityl resin: 2-Chlorotrityl chloride resin 
CPT: camptothecin 
DBU: 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCM: dichloromethane 
DMAP: 4-Dimethylaminopyridine 
DMF: dimethylformamide 
EDCI: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
Fmoc: fluorenylmethyloxycarbonyl 
HOBt: Hydroxybenzotriazole 
Lys: lysine  
MeOH: methanol 
NMM: N-Methylmorpholine 
THF: tetrahydrofuran 
TIS: Triisopropylsilane 
Wang Resin: p-Benzyloxybenzyl alcohol resin 
Z: Benzyloxy-carbonyl 
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1. Introduction 
Pancreatic carcinoma, of all types of cancers, has proven to be one of the hardest to 
diagnose and treat.
1
 Diagnosis for pancreatic cancer often does not occur until later stages when 
the tumor has metastasized and spread to a point where classic treatment methods are no longer 
viable.
2
 This late detection is due to a lack of symptoms and difficulty in detection as the 
pancreas lies under other major organs.
2 
 Survival rates for pancreatic cancer are less than 5% 
over five years after diagnosis. Colorectal cancer is the third most commonly diagnosed cancer 
among men and women and in 2012 accounted for 9% of cancer deaths in the United States.
3 
Depending on the origin of the colon cancer, survival rates for five years can vary from as high 
as 90% for cancer developing from polyps to lower than 30% for undifferentiated carcinoma, 
small cell carcinoma, signet ring cell carcinoma, and melanoma histologic groups.
4
 When 
detected at an early stage the survival rate for colon cancer is 90% but only 39% of cases are 
diagnosed at that stage.
3 
The survival rate dips down to 58% for 10 years, and continues to 
decrease from that survival rate.
3 
With these potential low outcomes for colon cancer and 
extremely low outcomes for pancreatic cancer, there is great need for improved treatment 
methods. Current methods of treatment include surgery, chemotherapy and a combination of the 
two. 
 Surgery has played a key role in the treatment of the pancreatic carcinoma in the past, as 
well as other types of cancers such as breast cancer, because the disease has largely drug 
resistant. Although removing the tumor can increase survival, local reoccurrence occurs in 85% 
of patients who undergo surgery alone for treatment.
5
 Also, not all patients diagnosed have 
resectable, non-metastatic tumors, 80% of patients generally have non-resectable advanced or 
metastatic tumors.
6 
 Surgery alone is not a sufficient treatment for pancreatic cancer.
7 
A 
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combination of surgery and radiation improves the survival times and quality of life; but, it still 
has a low survival rate with some patients showing a 0% response rate.
2
 While a combination of 
surgery and chemotherapy is the most likely source of progress in treatment, new drug therapies 
are needed for improved outcomes.
5 
 Surgery has often proved successful for colorectal cancer but usually requires a 
combination with chemotherapy to fully eradicate the cancer.
3 
It is the most common treatment 
for this type of cancer and proves successful when the tumor can be removed.
3 
However, for 
ultimate success, the treatment with chemotherapy both pre- and post-surgery is required rather 
than surgery alone.
3 
This treatment is where improvements can be made. 
 There are a variety of drugs currently available for treatment and eradication of 
pancreatic cancer in patients. A common issue with many of them is the uniquely high resistance 
of pancreatic cancer and the extreme toxicity of the drugs. The currently preferred drug choice is 
gemcitabine though it has had a low response rate and still unfavorable survival rates. 
Gemcitabine has been combined with other drugs like Erlotinib and Bevacizumab in an attempt 
to improve outcomes.
8,9
 Though the use of combination therapies may provide a new pathway to 
increased survival, such methods lead to increased toxicity, which in turn causes complications 
such as bleeding, thrombosis and hypertension.
9
 There are other compounds, such as 
Sansalvamide A derivatives, that are being tested that have equivalent survival rates as current 
methods but do not show improvement. However, current methods of treatment have dismal 
survival rates.
10
 Gemcitabine is the only drug that can be considered as a first-line therapy for 
treatment, though it has a minimal effect on survival and in trials nearly half the patients required 
hospitalization for toxicity from the treatments.
5
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 Chemotherapeutic treatment for colorectal patients include monoclonal antibody 
therapies currently approved by the FDA.
3 
These drugs are Bevacizumab, which blocks the 
growth of blood vessels to the tumor, and Cetuximab and Panitumumab which both block the 
effects of the hormone-like factors that promote cancer growth.
3 
However, chemotherapy as a 
treatment is limited by the toxicity of the drugs which may prevent the required dose from being 
given, especially to patients over the age of 70.
3 
This type of treatment is effective when the 
cancer has not spread and can easily be removed, but colorectal cancer has the possibility of 
spreading to other vital organs, which can decrease treatment effectiveness and survival rates 
greatly.
4
 
Nanosomes, nanospheres, nanotubes and other nanoparticles have all been used for the 
delivery of anti-cancer agents, incorporating drugs that have been too toxic or too difficult to 
deliver previously.
11
 Studies done comparing the uses of the various structures and forms show 
that some forms are more favorable.
11
 Stabilized structures work better than non-stabilized, 
defined structures are more effective than random aggregates, and encapsulated drugs show less 
toxicity than non-encapsulated structures when creating treatments for cancer therapies.
11
 These 
structures provide a potentially safe and more efficacious method of delivery.
11
 More research is 
needed to show the mechanism by which these nanostructures work, but their efficacy has been 
shown. 
 Nanotubes are functional, technological developments that provide a variety of structure 
types, uses, and features. They can naturally occur at all scales and play important roles in 
biology, such as micelles, for intracellular and extracellular transport, and tubulin.
12
 
Nanostructures for biological function can self-assemble with the aid of enzymes or for our 
purpose without the aid of enzymes.
12-13
 Nanotubes and other nanostructures have been used for 
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various purposes such as detecting the activity of enzymes, controlling the fates of cells, and 
developing drug delivery systems.
 12
 Therefore self-assembling nanotubes provide a promising 
basis for a targeted drug delivery system, as other nanostructures have been implemented for 
various biological uses both naturally and artificially.
12 
The basis for using nanostructures is both to protect the encapsulated drug as well as to 
exploit the enhanced permeability and retention effect (EPR) to accumulate the pro-drug in 
tumor tissues. As tumors grow at an accelerated rate, they must provide a sufficient supply of 
oxygen and nutrients to maintain their growth. These newly formed tumor vessels grow in 
abnormal form and have a defective structure, which leads to enhanced vascular permeability, 
large gaps form in between endothial cells allowing for the entrance of nanoscale molecules.
14, 15, 
16 
It has been observed that particles on the scale of 10-100 nm accumulate in tumor tissues due 
to the leaky vasculature nature of blood vessels surrounding tumor tissues.
15 
Nanoparticles, such 
as gold particles, carbon nanotubes, and more, have shown promise for the development of novel 
cancer diagnostic techniques and have the ability to enter tumor sites due to the EPR effect and 
the high O2 demand in contrast with healthy tissue because of their increased growth rates.
17,18,19
 
But these current particles have difficulty in controlling size and surface chemistry. Also, these 
structures show a high potential for toxicity in humans, which limits drug development and 
creating models for delivery.
20,21 
While pancreatic cancer has shown decreased vasculature in 
metastatic tumors, creating a hypertensive state or use of angiotensin II can augment the EPR 
effect in hypovascular tumors with minimal effect on normal tissue when the augmenting drugs 
are administered simultaneously with the treatment.
22 
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Figure. 1 Enhanced permeability and retention effect
23 
Camptothecin is one of the many drugs that have been investigated to use as a treatment 
for a broad range of cancer cells.
24
 Its mode of action is through the inhibition of topoisomerase I 
which results in DNA strand breakage during replication thus leading to cell apoptosis.
24
 
However, in its natural form it is highly toxic and lethal in quantities needed for remission.
24 
The 
other issue with camptothecin is that its natural form is insoluble in water, a property necessary 
for infusion treatment. Also, the key portion of camptothecin is the lactone (E-ring) portion of 
the drug that at physiological pH tends toward the open carboxylic form, rendering the drug 
inactive.
25 
Albumin proteins in the blood also bind to the camptothecin and can render it 
inactive.
25
  However, soluble derivatives of this compound, such as topotecan and irinotecan, 
have shown some tolerability and activity against various types of tumors such as small cell lung 
cancer, breast cancer, and in cell lines where other drugs have encountered resistance.
24
 
Camptothecin, if modifications can be made to increase solubility, has potential for efficacious 
12 
 
treatment for pancreatic cancer if the toxicity can be kept at a minimum and targeting of a 
modified form can be increased.
24
 
 
Figure 1.2. Camptothecin and Modified forms 
The Parquette lab at the Ohio State University has developed self-assembling 
nanostructures, without the aid of enzymes for various purposes. These structures include 
nanotubes, fibers, spheres and random aggregates with a focus on creating organized structures. 
The nanotubes self-assemble due to their amphiphilic properties.
26
 Within the peptide-dendron 
model created,the hydrophilic lysine and the hydrophobic NDI cause the compounds to self-
assemble into nanotubes in an aqueous environment.
26
 Organized structures have been shown to 
be more effective for drug delivery systems and tend to increase stability.
11
 One of the worries 
with toxic cancer drugs like camptothecin is the threat of death to other cells in the body. 
Exploiting the EPR effect will allow for cancer cells to be targeted where as normal cells and 
tissue, which do not exhibit leaky vasculature, will remain unaffected.
16
 Therefore, allowing for 
an increase in drug dosage without the toxic effects that are typically seen when giving high 
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doses of campothecin, and the standard treatment gemcitabine. Placing the highly toxic drugs in 
peptide based nanoparticles can reduce their toxicity but increase their efficacy.
11
 When placed in 
large cyclodextrin-based polymer structures, the camptothecin conjugate shows increased tumor 
activity when compared to campothecin alone, or modified form, irinotecan. 
24,27,28  
Amphiphilic 
cyclodextrin models have also shown increased drug dosing and antitumor activity when 
compared with modified camptothein forms and other nanoparticle models.
29
 
 
Figure 1.3. Hui Shao’s model and image of nanotubes created using the peptide-dendron model. 
Another feature of the nanotubes model is the potential for a dynamic system. A dynamic 
system means one where the nanostructure of a compound in solution can be changed by 
changing the solution components, for example pH, salt concentration and activity of solution. 
This system is different from many carbon nanotubes and other inorganic systems which create 
rigid and unchanging structures. As a tumor produces a different environment than exists in the 
blood, a dynamic system if designed correctly could allow for an easy release of the drug by 
hydrolysis once the nanotube enters the tumor, therefore maintaining targeting and increased 
chance of delivery.
30
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The objective of this project is to create a self-assembling nanotube system that 
incorporates camptothecin. The goal is for the compound to be soluble in phosphate buffer 
solution (PBS), a mimic for human blood that is suitable for testing conditions, and to form 
nanotubes that encapsulate the drug and are within 10-100 nm to allow to exploitation of the 
EPR effect. The current design for targeted drug delivery nanotubes is based on of the NDI-
lysine model. Lysine methyl ester will be used for the hydrophilic portion of the compound and 
camptothecin, a nearly flat aromatic (similar structure is found in NDI) will be used for the 
hydrophobic portion. These two pieces will be connected by succinic acid. By mimicking the 
NDI-lysine model, the compounds are likely to form assemblies with the camptothecin 
encapsulated, as was discussed a key feature of success for drug delivery systems.
11
  Because of 
the hydrophilic lysine, the nanotubes, like their predecessors will be soluble in water, a key 
feature for intravenous medicine. The compound will be made up of lysine methyl ester, succinic 
acid and camptothecin. Besides the toxic cancer drug, this compound uses compounds that 
naturally occur in the body, lysine being a natural amino acid and succinic acid also found in 
vivo and used in the Kreb’s cycle. Thus the only damaging feature is the camptothecin, which 
will theoretically only be in the cancer cells. The nanotubes by design can also be opened up 
inside the cells by hydrolysis if the ester linkage and the non-cancer drug parts can easily be 
handled by the cells. The proposed structure includes necessary key features as denoted by past 
studies while incorporating innovative ideas for increasing the efficacy of the delivery system. 
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Figure 1.4. Comparison of semi-conductor model with cancer drug model 
Compound 1.0 was synthesized in solution based reactions. The compound was then 
tested for solubility and nanostructure formation through circular dichroism scans, transmission 
electron microscopy. Compounds 2.0 and 3.0 were created on resin, cleaved and underwent 
similar testing methods. Compound 1.0 was then tested to determine if the structures were 
maintained when the nanostructure was formed in one solution and then placed in another 
solution, potential for dynamic system. 
Various nanostructures were created based on composition of the solvent as well as 
various changes to the polar head, hydrophilic portion, of the model. The model is based off of 
Hui Shao’s NDI design and includes the key components: a hydrophilic head and a flat, 
aromatic, hydrophobic body, which create an amphiphilic compound whose nature will drive the 
self-assembly. The hydrophobic portion will allow for π-stacking when placed in polar solution 
and will be forced to the inside of the structure. The hydrophilic head will have favorable 
interaction with polar solvents forcing it to the outside of the structure. These favorable 
(4.0) (1.0) 
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interactions will be the driving force for nanotube formation. Slight changes to the lysine were 
made based on the design changes that were done to the NDI design to try and crate different 
nanostructure formations. Changes made to that portion were shown to have large effects on the 
solubility and nanostructure formation of the NDI design.
30
 It was found that with the drug 
model design the slight changes in the lysine induced different assemblies. Also, different 
solution compositions, polarity and pHs were found to have an effect on the type of 
nanostructure formed. A time-delay experiment showed the potential for a dynamic system to be 
created based on the morphologies of tumors and compound structures.  
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2. Synthesis of Amphiphile 
 
The general design of the camptothecin derivative is based upon the NDI-lysine nanotube 
design.
24
 In replacement of the chromophore in NDI, camptothecin, another mostly flat and 
aromatic compound, will be used to create the pi-stacking to align the compounds into "strips." 
The lysine end will be kept with a methyl ester to form the polar head of the compound. The 
same amphiphilic nature should be the same powerful driving force in creating bilayer tubes.  
Compound 1.0 was created using solution synthesis to maximize yield. However, the 
inherent lack of solubility of camptothecin made further reactions and modifications difficult 
using solution based synthesis alone. Therefore both compounds 2.0 and 3.0 were made via 
solid-support synthesis using the appropriate resin (Wang and Trityl Resin). Instead of a base for 
a long polypeptide, the resin served as a solid, stable protecting group for the lysine and it 
allowed for easier modifications without unwanted precipitation occurring mid-reaction prior to 
completion. Solid support synthesis also allowed for only one purification reaction which 
prevented the loss of camptothecin compounds on silica-based columns after each solution 
reaction. 
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2.1 Lysine Derivative Synthesis (Compounds 1.1-1.2) 
 
 
Boc-Lys-OMe is not readily available is made through methyl esterification of the 
protected amino acid Boc-Lys(Z)-OH.
34
 Boc-Lys(Z)-OH was dissolved in dry DMF (0.35 M), 
and methylated via methyl iodide and sodium bicarbonate then isolated via extraction from 
aqueous solution with DCM 1.1. Deprotection of the side chain amine is done through 
hydrogenation Pd/C and  isolated through filtration through celite, 1.2. Both reactions form clear 
oils which are not crystallized prior to next steps, NMR shows purity.  
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2.2 Campothecin Linker Synthesis (Compound 1.3) 
 
 Camptothecin (CPT) was attached to succinic acid to create a linker by which to attach 
the lysine.
31
 
 
 
 
The succinic acid is attached to the camptothecin as a linker by reacting the camptothecin 
with succinic anhydride and DBU. Reaction is worked up through acidification and extraction. 
Product is purified via trituration in MeOH 1.3.  
20 
 
2.3 Methyl Ester Amphiphile Synthesis (Compounds 1.4 and 1.0) 
 
 
The modified and Boc protected lysine was then attached to the camptothecin-linker via 
EDCI coupling with DMAP dissolved in DMF and stirring for 2 days. The solvent from the 
resulting solution was evaporated. The product is purified via column chromatography, 1.4. The 
Boc protecting group was then be cleaved under acidic conditions. The product was then be 
purified by HPLC and solution with product was placed on lyopholizer to remove H2O, 1.0. The 
solid, 1.0, was then used for studies in CD, UV, and TEM.   
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2.4 Free Acid Amphiphile Synthesis (Compound 2.0) 
 
 
 The free acid was synthesized on Trityl-Resin solid support according to standard 
procedures as demonstrated in the above diagram. Protected lysine was first attached to 
deprotected resin. The side chain protecting group was cleaved and the camptothecin linker was 
attached. The amino group was then deprotected and the compound was cleaved from the resin. 
The product was precipitated after the solvent was removed and purified by HPLC.   
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2.5 Amide Amphiphile Synthesis (Compound 3.0) 
 
 
The amide was synthesized on Rink-Resin solid support according to standard procedures 
as demonstrated in the above diagram. Protected lysine was first attached to deprotected resin. 
The side chain protecting group was cleaved and the camptothecin liker was attached. The amino 
group was then deprotected and the compound was cleaved from the resin. The product was 
precipitated after solvent was removed and purified by HPLC. 
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2.6 Compound Description and Solubility 
 
Campothecin in its natural form is not soluble in the majority of solvents, including water 
which is a requirement for intravenous injection, the method by which chemotherapeutic agents 
are typically delivered. To make a viable drug, ideal solubility for testing is in phosphate buffer 
solution (PBS) as a mimic to physiological condition.  
Compound 1.0:  a yellow, fluffy solid, similar in color to natural camptothecin. Solubility 
in water, PBS, and organic solvent (TFE) was determined by creating 10 mM solutions. The 
compound was placed in appropriate amount of solvent and then sonicated with mild heating to 
induce complete solvation. Despite its inherent lack of solubility, the final compound was readily 
soluble in TFE, forming a bright yellow solution. The final compound was also soluble in both 
H2O and PBS at 10 mM concentration after slight agitation via sonication and slight application 
of heat.  
Compound 2.0: a yellow, fluffy solid, similar in color to natural camptothecin. Solubility 
in PBS after agitation via sonication and mild heating was determined for 5.7 mM solutions with 
turbid appearance. Not soluble in neutral water. 
Compound 3.0: orange/yellow, fluffy solid, darker in color than natural camptothecin. 
Compound was not soluble in neutral aqueous solution.  Compound was soluble in PBS . 
Solution had slightly turbid appearance and required sonication for complete solvation. 
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3. Results/Discussion  
 
3.1 UV and CD Characterization 
 
3.1a Methyl Ester Amphiphile 
 
 Samples of compound 1.0 were prepared in each H2O, PBS and TFE solutions at 10 mM 
and aged 2-4 days. Solutions were then diluted to specified concentration just prior to testing. 
 
Figure 3.1 Comparison of UV scans of 3 dilutions of Compound 1.0  at 0.5 mM concentrations 
 
The UV patterns of all three solutions are similar in the peak wavelengths. Absorbance 
occur at 210 nm, 250 nm, 350 nm and 360 nm for each of the solutions. The peaks in the TFE 
solution have higher relative absorptions than either the H2O or PBS solutions. However, there is 
also a distinct difference in the relative absorptions of the H2O and the PBS solutions. The more 
defined aggregates of the H2O (nanotubes) result in a higher absorbance in the UV than the 
random aggregates that formed in the PBS solutions. Comparing this result with the TFE which 
also formed defined aggregates, fiber structures, the more defined aggregates result in higher UV 
absorbance than the less defined aggregates. These peaks also align closely with the peaks or 
directly between two peaks that occur in each of the CD patterns. 
25 
 
a)                                               b) 
 
c)            d) 
 
Figure 3.2 a) CD and UV of 0.5 mM solution in H2O after 4 days of aging at 10 mM b) CD and 
UV of 0.5 mM solution in PBS after 4 days of aging at 10 mM c) CD of 0.5 mM solution in TFE 
after 2 days of aging at 10 mM d) Comparison CD of all 3 diluted solutions of 0.5 mM 
concentration (all CD measurements are in deg*cm
2
dmol
-1
) 
 
Each of the circular dichroism (CD) scans display peaks near 350 nm and between 200 
and 250 nm which correlate to the absorptions seen in the UV patterns. . The UV absorptions of 
the three solutions all fall either at a peak or at the midpoint between two peaks. This result 
indicates that the UV absorptions are coordinated to the same stacking or aggregation patterns as 
indicated by the CD. Peak patterns in the UV spectra indicate the creation of chirality beyond the 
26 
 
camptothecin chiral centers suggesting stacking of the compound occurred  interactions. At 
first glance, all three CD patterns show similarities in their peak locations. However, placing all 
three sets of data on the same graph (fig 3.1d) shows very clear distinctions between the three 
patterns. All three solutions have a peak at 225 nm and then an inverse peak when at 250 nm But 
the three solutions display unique patterns between 300 and 400 nm that differentiate them. The 
TFE solution appears to be an exaggeration of the H2O solution. But, the compound dissolved in 
PBS shows a distinct pattern that does not mimic either of the other two. The three unique patters 
displayed in CD indicate that it is very likely that three different nanostructures will emerge 
when observing the solutions with a TEM, as unique patterns reflect unique structure 
formations.
32
 However, none of the patterns line up with patterns CD patterns observed with the 
NDI based nanotubes.
13, 26, 32-33
  
3.1b Free Acid and Amide Amphiphiles 
  
Figure 3.3 UV and CD of Free Acid (2.0) and Amide Amphiphiles (3.0) in PBS. (all CD 
measurements are in deg*cm
2
dmol
-1
) 
 
The CD and UV scans were performed on the compounds 2.0 and 3.0 after 7 days of 
aging in 8.7 mM and 5.3 mM solutions respectively. Both solutions were then diluted to 0.125 
mM and 0.5 mM respectively for testing. Both amphiphiles show similar peak patterns between 
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350 and 400 nm as well as cotton effects at 250-265 nm and a final peak 225 nm. After 
normalization, the free acid amphiphile (2.0) shows higher peaks in the CD scans than the Amide 
(3.0) by a factor of 10. The UV absorptions are also stronger but not to the same scale. These 
similarities indicate that a similar pattern of stacking and nanostructure formation has occurred. 
This hypothesis was later confirmed by the formation of similarly sized nanotubes visualized by 
TEM. 
3.1c Comparison of 3 Designs 
  
Figure 3.4 UV and CD of 3 Designs in H2O and PBS. (all CD measurements are in 
deg*cm
2
dmol
-1
) 
 
Comparing the CD and UV patterns can shed light on similarities that may exist in the 
amphiphile stacking and nanostructure formation. The methyl ester design (1.0) was scaled to 
increase the relative peak heights for accurate comparison. As stated above, compounds 2.0 and 
3.0 designs show similar CD excitation patterns but differ by a factor of approximately 10 in 
strength. This similarity indicates that the two will follow a same stacking pattern. Compound 
1.0 has a dramatically different peak pattern in water where it formed nanotubes in comparison 
with the other two patterns as well as over 100 fold difference in strength of peaks. The near 
inverse excitation pattern between 350 nm and 400 nm suggests that the camptothecin is stacking 
28 
 
differently perhaps with an oppositely styled twist. Though while a different pattern emerges, the 
excitations occur at similar wavelengths indicating that camptothecin and lysine stacking is still 
occurring just in a different manner. The TEM images confirm a different nanostructure in terms 
of wall width but indicate no difference in overall formation (sheet-stacking theory explained 
below). 
The UV patterns show similar absorbencies at the same wavelengths that excitations in 
the CD were observed. The differences in overall absorbance are explained by the difference in 
the concentration of the samples when testing occurred. Both the amide and the methyl ester 
were observed in 0.5 mM concentrations which allow comparison. The absorption is 
significantly decreased in the amide solution in comparison to methyl ester and is smaller than 
the free acid absorptions which were taken a smaller concentration (0.125 mM).  
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3.2 TEM Characterization 
 
 Sample dissolved in 10-13 mM solutions in water, PBS or organic solvent. Samples then 
prepared for TEM
12: 10 μL drops of sample solution were applied to carbon-coated copper grid 
(Ted Pella, Inc.) for 2 min and after removal the excess solution with filter paper, the grid was 
floated on 10 μL drops of 2 wt% uranyl acetate solution for negative stain for 2 min. The excess 
solution was removed by filter paper. The dried specimen was observed with Technai G2 Spirit 
instrument operating at 80 keV. The data were analyzed with Image pro software. 
3.2a. Methyl Ester 
   
Figure 3.5 Nanotubes formed in 10 mM solution of H2O and diluted to 0.5 mM for imaging. a) 
Two sets of paired nanotubes crossing after 4 days. b) Individual nanotubes with distinct walls 
after 7 days. c) Cluster of nanotubes after 7 days (all scale bars measure 500 nm) 
 
 After four days of aging in 10 mM solution and another three days of aging at 0.5 mM 
concentration, TEM images were taken of the aqueous solution. The images indicate the 
formation of nanotubes. The nanotubes were generally seen in clusters as in Fig. 3.5c, where 
individual nanotubes were difficult to distinguish from one another. Isolated nanotubes were 
observed and characterized, as in Figs. 3.5a and 3.5b. The nanotubes were found to have a total 
diameter of 95 nm, within the 10-100 nm limit for the EPR effect, and wall widths of 20 nm. The 
approximate length of a single nanotube was measured to be 2 nm. The wall thickness and wide 
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hole through the middle of the tube indicate a sheet stacking and then rolling theory. The 
compound stacks with the hydrophobic portions lining up head to head and stacking next to each 
other forming sheets.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Sheet Stacking Theory, multiple sheets (2+) stack and roll to form tube. a) view of 4 
stacked bi-layers of amphiphile sheet. b) single amphiphile (2 nm). c) view of nanotube from 
side. d) view of nanotube at angle 
       
 These sheets are formed on top of one another and proceed to roll into a tube. A similar 
stacking has been observed with tetra-peptide models formed by other lab members as well as 
structures proposed for the NDI-peptide compound that formed nanotubes.
26
 TEM images 
determine the wall thickness to be 20 nm which suggests the stacking of 4 sheets together, as 
each sheet measures 5 nm, which then proceed to roll. This stacking theory allows for the 
 
5 nm 
a) b) c) 
d) 
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hydrophobic portions to be maintained together and protected from the aqueous solution. It is the 
hydrophobic stacking that is the driving force for the nanotube formation.
26 
The measurements 
for tube diameter and wall thickness are consistent throughout the images taken. Thus, a 
stabilized and defined structure has been made that encapsulate the drug; though, there is slight 
variation on the length of each tube, all near 1 micron, some larger and some smaller. None 
shorter than 500 nm was isolated. The isolated tube has a length of slightly more than 1 micron 
(Fig. 3.3b), but definitive measurements of other images are difficult to obtain with the clustering 
of the nanotubes. The clustering obscures the ends of the tubes. The aqueous assembly in all 
other aspects meets the ideal aspects for drug delivery systems.
11 
 
   
Figure 3.7. Nanostructures formed in 10 mM PBS solution, aged 4 days, diluted to 0.5 mM for 
imaging. a) Partial β-sheet formation, surrounding by random aggregates. b) Small fibril 
structures. c) Random aggregate formation (a and b scale bars measure 500 nm, c measures 2 
microns) 
 
After 4 days of aging at 10 mM concentration and then 2 days at 0.5 mM concentration, 
the above images were taken via TEM. It can be observed that unlike in water, no stable 
aggregates form in PBS. A variety of structures appeared including disrupted β-sheet formation, 
random fibers and, for the majority of the grid, random aggregates as in Fig. 3.7c were observed. 
While, the CD scans indicate that stacking had occurred of the lysine and the camptothecin, the 
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stacking appears disordered and unstable. The disarray observed in the PBS images is most 
likely due to salt inference of the stacking of the different portions of the compound. Interactions 
of the hydrophilic portions of the compound and the salts would disrupt stacking effects seen in 
the water solutions. The camptothecin is not a completely planar structure, as was the NDI 
structure used in the semiconductor model. Thus, its stacking ability is decreased from the onset. 
Without the aid of the hydrophilic portions, it appears the hydrophobicity of the camptothecin is 
not enough to force stacking, β-sheet, and tubular formation. 
 
   
Figure 3.8. TEM images of TFE solutions displaying fibers a) & b) 10 mM solution after 5 days 
aging, random fibers. c) No nanostructures in 10 mM solution diluted to 0.5 mM solution for 
imaging. (all scale bars measure 500 nm) 
 
 The compound was readily soluble in TFE solution and did not require agitation or 
heating to obtain complete solubility at 10 mM. After 5 days of aging, images were taken of the 
10 mM solution. Images of large clusters of nanofibers were observed (Figs. 3.8a and 3.8b). 
However, the diluted solution, 0.5 mM, showed no nanostructure formation (Fig. 3.8c) despite 
excitations in the CD spectra observed at that concentration after 2 days of aging. Low 
concentrations may not have close enough interactions of the compound to yield visible 
nanostructures via TEM despite the CD results. However, as structures are observed at higher 
concentrations, it can be said that self-assembly occurs in TFE. 
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All three solutions yielded differing CD excitation patterns and different nanostructures 
in TEM imaging, as would be expected. The UV absorptions occurred at the same wavelengths 
for all three solutions and aligned with the CD excitations. 
3.2b Free Acid Amphiphile 
   
Figure 3.9. TEM images of compound in 5.7 mM solution after three days of aging in PBS. 
Scale bars a) and b) measure 500nm, c) measures 100nm. 
 
 Compound 2.0 was not readily soluble in PBS; solution was slightly heated and then 
sonicated for an hour to aid in solubility. Compound was aged for three days, prepared and then 
imaged with via TEM. Images indicate the formation of nanotubes. The nanotubes are between  
80-175 nm in diameter with the majority of tubes having a diameter between 80-100 nm, Fig. 
3.9c shows a consistent diameter of 92 nm for the right nanotube. The nanotubes have a wall 
thickness of 16 nm. This size indicates a similar formation pattern to the tubes imaged of the 
methyl ester amphiphile in water, 3 layers. The smaller wall thickness would indicate the 
stacking of three sheets as opposed to four due to the width of a bilayer being 5 nm.  
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Figure 3.10. Sheet Stacking Theory, multiple sheets (2+) stack and roll to form tube. a) view of 
3 stacked bi-layers of amphiphile sheet. b) view of nanotube from side. c) view of nanotube at 
angle 
 
As opposed to the methyl ester, the PBS solution aided in the solubility in comparison 
with water and produced stabilized aggregates. The increased salt concentration of the solution, 
and thus anionic species concentration, increased the stacking and formation of tubes. This 
anionic effect has been seen with other nanostructures to be affecting the formation and can have 
a drastic effect.
34 
The salts in solution interact favorably with the zwitterion and aromatic 
regions, as opposed to unfavorably as seen with the methyl ester amphiphile, to make tube 
formation thermodynamically favorable.  
 a)  a
) 
a) b) 
c) 
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3.2c Amide Amphiphile 
   
Figure 3.11. TEM images of amide amphiphile after three days aging in PBS. a) broken 
nanotubes/formation of nanotubes. b) and c) full and stable nanotube. Scale bars 500 nm. 
 
 Compound required sonication in order to become fully soluble at high concentrations in 
PBS. After 3 days aging, TEM images were taken of concentrated samples which show nanotube 
formation. Nanofiber formation was not seen in images of the amide amphiphile in PBS in 
contrast with the Free Acid amphiphile which displayed fibril and nanotube formation after the 
same aging time. Nanotubes formed in PBS solution do not all form as the same diameter and 
wall width in contrast with the other two compounds which display equal diameter and wall 
width across all nanotubes imaged. The nanotubes formed from the amide amphiphile show a 
range of dimensions: 70-95 nm in diameter and 18-26 nm in wall width. A larger diameter size 
did not always coordinate with a thicker wall width. The size of the tubes and wall widths 
indicate a similar assembly process as other two compounds, specifically compound 2.0 due to 
similarities in the CD scans but with 3-5 β-sheet stacks. 
 
***Study done with PhD. candidate Se Hye Kim 
  
36 
 
3.3 Time Delay Experiment- Dynamic System Test 
  
 Solution  of Compound 1.0 was prepared at 10 mM concentration in H2O and aged for 4 
days. Solution was then diluted to 1.0 mM in H2O for baseline UV and CD. Concentrated H2O 
solution was then diluted to 1.0 mM solution using PBS. CD was used to determine if change in 
nanostructure, after having been formed in one type of solution, occurs when solution 
composition has been changed. 
 
Figure 3.12 Dynamic System Test CD and UV comparison. t= time CD scan was initiated 
starting at 800 nm, ~ 3 minutes to 350 nm 
 
The two CD forms show unique excitations patterns that can be distinguished from 
another, indicating the two different nanostructure formations. The initial dilution in water 
demonstrates the same peak pattern as observed in the previous experiments from which the 
nanotubes were imaged. The CD scan takes approximately 3 minutes to go from 800 nm to the 
350 nm range where clear differences in the spectrum may be observed. The times represented in 
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the graph are time after solution was diluted at the beginning of the scan (800 nm). The first scan 
taken of the dilution (t=0) in PBS, shows a change in pattern from H2O to a pattern matching the 
previously taken PBS patterns. All measurements taken after the PBS dilution show the PBS 
solution excitation pattern. This data indicates that there was a change from the nanotube 
structure that the H2O pattern indicates to the random aggregate structure that formed in PBS 
solutions. This result occurred despite the aging in water and dilution in PBS. Therefore, the 
compound is able to have a complete confirmation and stacking change immediately (within 3 
minutes) of having an environmental shift. The UV patterns of all three solutions match each 
other as well as match the original UV patterns taken from the samples that were imaged. There 
is a slight depression in strength going from the H2O dilution to all of the PBS dilutions. This 
result matches the depressions that occur when each of the solutions were aged and diluted via 
the same medium. 
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4. Conclusion  
 
The three models designed and tested showed slightly different assemblies and had 
varying solubilities in water and PBS (soluble in 10mM or greater solutions was defined as 
soluble). All three formed nanotubes but of the three only the compound 2.0 and the 3.0 showed 
both solubility and nanotube formation in PBS, solution used as a mimic for human blood 
conditions for purposes of testing and imaging. The amphiphilic nature of the designs causes 
their assembly into nanotubes, driven by hydrophobicity. The increase in polarity at the 
hydrophilic head decreased the solubility of the last two designs leading to their limited 
solubility, soluble in PBS but not neutral water. The ions in the PBS solution interacted with the 
compound 1.0 in an unfavorable manner leading to the formation of random aggregates as 
opposed to stabilized nanostructures as was seen in water. However, due to the anionic effect 
where the ions in the PBS solution interact with the hydrophilic head group, the opposite was 
demonstrated by the compound 2.0 and 3.0 designs. Both showed an increase in stacking (as 
seen in CD excitation strength increases) and formed stabilized nanotube structures that 
demonstrate similar formations. The increase in the polarity of the solution could also cause 
increased camptothecin stacking in the last two designs as well, leading to an increase in CD 
excitation signal and could lead increased stabilization. 
It was shown that a dynamic system is possible but further modifications need to be 
made; such as increasing the polarity of the head, decreasing the length of the linker, or changing 
the number of amino acids used as the polar portion (making a di- or tetrapeptide) that are 
sensitive to slight change in acidic conditions that would occur in tumor cell environments.  
Possible modifications to the design, such as changing the linker length or drug type, 
could lead to a smaller and more stable nanotube. This change would allow for the EPR effect to 
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be taken advantage of even more. Also, the shorter linker would cause a more rigid structure 
potentially increasing its sensitivity to slight environment changes. 
The designs that show nanotube formation in PBS (human blood mimic) will be tested 
for their efficacy and toxicity in mice models of pancreatic carcinoma in the lab of Dr. Mark 
Grinstaff at Boston University.   
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5. Experimental 
 
General Methods. All reagents were used as received unless otherwise noted. All 
solvents used in reactions were distilled using appropriate measures prior to use. 
Dimethylformamide was dried and stored over 4 Å molecular sieves. All reactions were 
performed under nitrogen unless otherwise indicated and monitored by TLC with spots detected 
under UV light. Circular dichroism (CD) spectra were taken on a AVIV 202 CD Spectrometer. 
Transmission Electron Microscopy (TEM) was performed on a Technai G2 Spirit instrument 
operating at 80 kV. 
1
H NMR were recorded at 250 or 400 MHz and 
13
C NMR were recoreded at 
400 MHz on a Bruker DPX-250 or DPX-400 instrument as noted. Chromatographic seperations 
were done on silica gel 60 (230-400 mesh, 60 Å) using the noted solvents. All water used for 
solutions was HPLC grade. 
Peptide Resin Synthesis. 
 Resin based synthesis was done using either Rink Amide Resin (0.59 mmol/g) or Trityl 
Resin(1.00 mmol/g). Attachment of lysine to rink amide resin was performed by Fmoc-Lys(Mtt)-
OH, 1,3-diisopropylcarbodiimide (DIC), and 1-hydroxybenzotriazole (HOBt) (300 mol% each 
relative to resin) in 1:1 DMF:DCM for 2 h. Trifluoroacetic acid (1%) in DCM was used for Mtt 
deprotection. Attachment of lysine to Trityl Resin was performed by Fmoc-Lys(Alloc)-OH (200 
mol%) , N,N-Diisopropylethylamine (DIPEA) (400 mol%) in DCM for 24 h. Alloc was 
deprotected by Pd(PPh2)4 (50 mol%), N-methyl-aniline (450 mol%), and PPh3 (450 mol%). 
CPT-linker was then attached via (300 mol% each) 4-Dimethylaminopyridine (DMAP), 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide (EDCI) and 1-hydroxybenzotriazole (HOBt) in DMF 
for 48 h. Piperdine (20%) in DMF was used for Fmoc removal. The CPT-peptide was cleaved 
from the resin by treatment with TFA/water/triethylsilane (95/2.5/2.5) for the Rank-resin and 5% 
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TFA/DCM for the Trityl Resin at room temperature for 2 h. Crude products were precipitated 
with cold ethyl ether and purified by reversed-phased HPLC on preperative Varian Dynamax 
C18 column and stored as lyopholized powders at 0°C. 
Circular Dichrosim (CD) Spectroscopy Measurement.  
CD spectra were recorded on an AVIV 202 CD spectrometer under a nitrogen 
atmosphere. Experiments were performed in a quartz cell with a1 mm path length over the range 
of 190-800 nm at 25 °C. 
Electron Microscopy Measurement- Negative Stain TEM.  
10 μL drops of dilute amphiphile (5-10μL) were applied to carbon-coated copper grid 
(Ted Pella, Inc.) for 2 min and. After removal the excess solution with filter paper, the grid was 
floated on 10 μL drops of 2 % wt uranyl acetate solution for negative stain for 2 min. The excess 
solution was removed by filter paper. The dried specimen was observed with Technai G2 Spirit 
instrument operating at 80 keV. The data were analyzed with Image pro software. 
Mass Spectrometry ESI. 
 Samples were dissolved in either water, MeOH or CH3CN and spectra was recorded on 
Bruker MicrOTOF (ESI).  
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Synthesis of Compound 1.1
35 
 
 
 
 In a 10 mL round bottom flask, Boc-Lys(Z)-OH (0.500g, 1.314 mmol) and NaHCO3  
(0.331 g, 3.942) were dissolved in DMF (4 mL).  To the reaction CH3I (0.210 g, 1.446 mmol, 
0.09 mL) was added in one portion. The reaction was stirred for 17 h and then diluted with 
EtOAc (20 mL). Organic solution was washed with H2O (2 x 15 mL) and brine (10 mL). The 
organic layer was dried with anhydrous sodium sulfate, filtered and organic solvent was removed 
in vacuo. Product was purified via column chromatography (10:1 CH2Cl2:MeOH, Rf: 0.6) 
yielding clear oil (0.378 g, 73%). 
1
H NMR (250 MHz, DMSO) δ 1.32-1.37 (m, 11H), 1.55-1.58 
(m, 2H), 2.96 (q, 2H, J= 5 Hz), 3.60 (s, 3H), 3.85-3.94 (q, 1H, J= 7.5 Hz), 5.00 (s, 2 H), 7.20-
7.23 (m, 2H); 7.31-7.37 (m, 4H); 
13
C NMR (400 MHz, DMSO) δ 14.03. 20.71, 22.72, 27.89, 
28.12, 28.85, 30.25, 35.77, 51.63, 53.47, 59.74, 65.07, 78.19, 127.64, 127.70, 128.31, 137.21, 
155.56, 156.09, 173.17; ESI-MS calculated for C20H30N2O6 [M+Na] calc= 417.1996, obs= 
417.1986; IR (DMSO) υ 3348, 3217, 3040, 1597, 1728, 1674 cm-1. 
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Synthesis of Compound 1.2
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 In a 10 mL round bottom flask, Boc-Lys(Z)-OMe (0.378 g, 0.9583) was dissolved in 4 
mL THF:MeOH (1:1). To the solution, 10% Pd/C (1 g) was added and the reaction was placed 
under H2 balloon. After 20 h stirring under H2, the reaction was filtered through a pad of celite, 
washed with MeOH (10 mL). The organic solvent was removed in vacuo yielding clear oil 
(0.057 g, 51%). 
1
H NMR (250 MHz, DMSO) δ 1.32-1.37 (m, 11H), 1.52-1.57 (m, 2H), 2.58-2.63 
(m, 2H), 3.6 (s, 3H), 3.85-3.94 (m, 1H), 7.25 (m, 1-2H), NMR peaks consistent with literature; 
13
CMR (400 MHz, DMSO) δ 14.05, 20.73, 27.56, 28.13, 28.81, 51.53, 52.56, 59.71, 77.91, 
78.12, 128.17, 174.30; ESI-MS calculated for C12H35N2O4 [M+H] calc= 261.1809 obs= 
261.1799; IR (DMSO) υ 3410, 3233, 1705, 1674, 1528 cm-1. 
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Synthesis of Compound 1.3  
 
 
 
 To a 25 mL round bottom flask with stir bar was added CH2Cl2 (13.1 mL). Camptothecin 
(0.150 g, 0.431 mmol) and succinic anhydride (0.129 g, 1.292 mmol) were added together and 
partially dissolved in solution. The solution was stirred and the reaction was cooled to 0˚C. The 
solution was cooled to 0°C, and DBU (0.196 g, 1.29 mmol, 0.193 mL) drop wise for 5 min and 
solution was stirred for 2 h. The reaction was monitored by TLC (10:1 CH2Cl2:MeOH) for 
disappearance of camptothecin. Upon completion, the reaction was washed with 5% HCl 
aqueous solution (20 mL) and product extracted with 10% MeOH in CHCl3 (3x, 50 mL). Organic 
layer was dried with anhydrous Na2SO4. Crude was triturated with MeOH to yield yellow solid 
(0.190 g, 0.424, 98%, m.p. (MeOH): 205-208°C). 
1
H NMR (250 MHz, DMSO) δ 0.90 (t, 3H, J = 
5.0 Hz), 2.15 (m, 2H), 2.50 (m, 2H), 2.74 (m, 2H), 5.30 (s, 2H), 5.48 (s, 2H), 7.13 (s, 1H), 7.72 
(t, 3H, J = 7.5 Hz), 7.87 (t, 1H, J= 7.5 Hz), 8.16 (t, 2H), 8.70 (s, 1H), 12.26 (s, 1H); 
13
C NMR 
(400 MHz, DMSO) δ 7.49, 28.35, 28.52, 30.35, 50.17, 66.26, 75.83, 95.09, 118.18, 127.93, 
127.72, 128.51, 128.99, 129.77, 130.36, 131.52, 145.21, 145.89, 152.38, 156.51, 167.14, 171.23, 
172.95; ESI-MS calculated for C24H20N2O7 [M+Na]= 471.1163, obs= 471.1187; IR (DMSO) υ 
3449, 1736, 1667, 1605, 1566 cm
-1
. 
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Synthesis of Compound 1.4 
 
 
 
 In a 10 mL round bottom flask, 2.1 (0.140 g, 0.3122 mmol), 1.2 (0.162 g, 0.6244 mmol), 
EDCI (0.120 g, 0.6244 mmol), and DMAP (0.076 g, 0.6244 mmol) were dissolved in DMF (1.56 
mL). After stirring for 48 hr, solvent was removed in vacuo and crude was purified via column 
chromatography (10:1 CH2Cl2:MeOH, Rf: 0.86) yielding orange, fluffy solid (165 mg, 77%, m.p. 
(CH2Cl2): 71-74°C). 
1
H NMR (400 MHz, DMSO) δ 0.90-0.93 (t, 3H, J= 7 Hz), 1.35-1.37 (m, 
11H), 1.38-1.90 (m, 2H), 2.15 (m, 2H), 2.38 (m, 2H), 2.59-2.61 (m, 2H), 2.74 (m, 2H), 3.60 (s, 
3H), 5.30 (s, 2H) 5.48 (s, 2H), 7.09 (s, 1H), 7.72 (t, 1H, J= 7 Hz), 7.87 (t, 1H, J= 7 Hz), 8.14 (t, 
2H, J= 9 Hz), 8.70 (s, 1H); 
13
C NMR (400 MHz, DMSO) δ 7.50, 22.81, 27.52, 28.10, 28.73, 
29.55, 30.22, 30.98, 40.53, 48.55, 51.61, 52.57, 53.47, 66.16, 75.83, 78.04, 78.21, 118.67, 
127.68, 128.31, 128.84, 129.69, 130.41, 145.82, 147.81, 152.28, 154.54, 155.64, 156.70, 167.27, 
169.88, 171.48, 174.41, 200.17; ESI-MS calculated for C36H42N4O10 [M+H] calc= 691.2974, 
obs= 691.2964; IR (DMSO) υ 3426, 1744, 1705, 1667, 1620, 1535 cm-1. 
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Synthesis of Compound 1.0 
 
 
 
 To a 5 mL flask was added 3.1 (40 mg, 0.0580 mmol). The solid was dissolved in CH2Cl2 
and TFA (0.36 mL) was added dropwise for 1 min. The reaction was stirred for 4 h and then 
solvent was removed in vacuo. Crude was dissolved in CH2Cl2 (5 mL) and solvent evaporated, 
repeated. Crude was purified by HPLC yielding yellow fluffy solid (26 mg, 76%, 
m.p.(CH2Cl/DMSO) 132-135°C: . 
1
H NMR (400 MHz, DMSO) δ 0.92 (t, 3H, J= 7 Hz),1.21-1.38 
(m, 4H), 1.62-1.75 (m, 2H), 2.15 (m, 2H), 2.37 (m, 2H), 2.67-2.83 (m, 2H), 2.90-3.11 (m, 2H), 
3.73 (s, 3H), 3.98 (m, 1H), 5.32 (s, 2H), 5.49 (s, 2H), 7.14 (s, 1H), 7.72 (t, 1H,  J= 7 Hz), 7.88 (t, 
1H, J= 7 Hz), 8.17 (t, 2H, J= 9 Hz), 8.28 (broad s, 2H) 8.72 (s, 1H); 
13
C NMR (400 MHz, 
DMSO) δ 7.49, 21.51, 28.35, 228.90, 29.54, 30.25, 50.18, 51.79, 52.73, 58.63, 58.96, 59.29, 
66.19, 75.82, 95.28, 118.72, 123.87, 126.65, 127.74, 127.94, 128.81, 129.70, 131.65, 145.83, 
147.80, 152.27, 156.57, 167.27, 169.86, 170.19, 171.51; ESI-MS calculated for C31H34N4O8 
[M+H] calc= 591.2449, obs= 591.2448; IR (DMSO) υ 3356, 3201, 1744, 1667, 1604, 1558 cm-1. 
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Synthesis of Compound 2.0 
 
 
 
See page 40 for synthesis. Yielded yellow, fluffy solid. (m.p. (H2O): 138-140 °C). 
1
H 
NMR (250 MHz, DMSO) δ 0.92 (t, 3H, J= 7 Hz), 1.23-1.38 (m, 4H), 1.68-1.70 (m, 2H), 2.15 (q, 
2H, J= 6 Hz), 2.35 (m, 2H), 2.74 (m, 2H), 3.03 (m, 2H), 3.84 (m, 1H), 5.31 (s, 2H), 5.49 (s, 2H), 
7.14 (s, 1H), 7.30 (t, 1H, J= 7H), 7.81 (t, 2H, J= 7Hz), 8.16 (m, 4H), 8.71 (s, 1H); 
13
C NMR (400 
MHz, DMSO) δ 7.53, 16.12, 23.10, 27.26, 28.51, 28.91, 29.62, 30.29, 34.42, 51.79, 57.01, 68.00, 
75.85, 95.85, 119.66, 121.57, 126.89, 128.57, 129.61, 131.97, 144.43, 146.02, 156.52, 170.95, 
171.11, 177.29, 180.98; ESI-MS calculated for C30H32N4O8 [M+H] calc= 577.2293, obs= 
577.2108; IR (DMSO) υ 3294, 3040, 1751, 1670, 1667, 1612, 1558 cm-1. 
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Synthesis of Compound 3.0 
 
 
 
 See page 40 for synthesis. Yielded yellow, fluffy solid (m.p. (H2O): 157-161 °C). 
1
H 
NMR (400 MHz, DMSO) δ 0.86 (t, 3H, J= 7 Hz), 1.28-1.31 (m, 2H), 1.55-4.60 (m, 2H), 2.10 
(m, 2H), 2.28 (m, 2H), 2.61-2.77 (m, 2H), 2.91-3.02 (m, 2H), 3.56-3.58 (m, 1H), 5.24 (s, 2H), 
5.43 (s, 2H), 7.07 (s, 1H), 7.65 (t, 1H, J= 7 Hz), 7.82 (t, 1H, J=7 Hz), 8.10 (t, 2H, J= 9 Hz), 8.64 
(s, 1H) 
13
C NMR (400 MHz, DMSO) δ 7.53, 21.73, 28.63, 28.90, 29.64, 30.34, 30.54, 33.72, 
50.42, 52.07, 66.41, 75.82, 95.11, 101.25, 118.80, 127.97, 128.62, 129.03, 129.78, 131.59, 
145.39, 145.94, 156.53, 167.25, 170.12, 170.34, 171.61, 173.61; ESI-MS calculated for 
C30H33N5O7 [M+H] calc= 576.2453, obs= 576.2460; IR (DMSO) υ 3449, 3302, 3171, 3043, 
1751, 1690, 1667, 1612, 1551 cm
-1
. 
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